Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole?

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 10, 2006, Pages 1147-1154

  De Boer, Wink ^a   De Wit, Niek ^b   Geldof, Han ^c   Hazelhoff, Bernard ^d   Bergmans, Paul ^d   Smout, André ^b   Tytgat, Guido ^e  

^a BERNHOVEN HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c IJSSELLAND HOSPITAL   (Netherlands)

^d Janssen Cilag ^*  (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Gastroesophageal reflux; Heartburn; Helicobacter pylori; Rabeprazole; Regurgitation; Treatment outcome

Indexed keywords

PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; ENDOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; STOMACH ACID; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSTOMIA;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; COHORT STUDIES; ENZYME INHIBITORS; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33749005386     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520600741546     Document Type: Article

References (38)

1. Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98 Suppl:S2-7.
2. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton III LJ. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-56.
3. Jankowski J, Jones R, Delaney B, Dent J. Ten-minute consultation: Gastro-oesophageal reflux disease. Br Med J 2002;325:945.
4. Verdu EF, Armstrong D, Fraser R, Viani F, Idstrom JP, Cederberg C, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995;36:539-43.
5. Labenz J, Tillenburg B, Peitz U, Idstrom JP, Verdu EF, Stolte M, et al. Helicobacter pylori augments the pH increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996;110:725-32.
6. Van Herwaarden MA, Samsom M, van Nispen CHM, Mulder PGH, Smout AJPM. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther 1999;13:731-40.
7. Koop H, Kuly S, Flug M, Eissele R, Monnikes H, Rose K, et al. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects. Eur J Gastroenterol Hepatol 1996;8:915-8.
8. Gillen D, Wirz AA, Neithercut WD, Ardill JES, McColl KEL. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole. Gut 1999;44:468-75.
9. Leodolter A, Glasbrenner B, Peitz U, Treiber G, Kahl S, Malfertheiner P. Intravenous omeprazole acts more rapidly in H. pylori positive patients with peptic ulcer bleeding. Gut 2002;51 Suppl II:A94.
10. Martinek J, Blum AL, Stolte M, Hartmann M, Verdu EF, Luhmann R, et al. Effects of pumaprazole (BY 841), a novel reversible proton pump antagonist and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1999;13:27-34.
11. Bercik P, Verdu EF, Armstrong D, Idström JP, Cederberg C, Markert M, et al. The effect of ammonia on omeprazole induced reduction of gastric acidity in subjects with Helicobacter pylori infection. Am J Gastroenterol 2000;95:947-55.
12. Verdu EF, Armstrong D, Idstrom JP, Labenz J, Stolte M, Dorta G, et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995;37:743-8.
13. Labenz J, Tillenburg B, Peitz U, Borsch G, Idström JP, Verdu E, et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997;92:576-81.
14. Williams MP, Usselmann B, Chilton A, Sercombe J, Nwokolo CU, Pounder RE. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo. Aliment Pharmacol Ther 2003;17:775-83.
15. Hatlebakk JG, Hyggen A, Madsen PH, Walle PO, Schulz T, Mowinckel P, et al. Heartburn treatment in primary care: randomized, double blind study for 8 weeks. Br Med J 1999;319:550-3.
16. Malfertheiner P, Lind T, Willich S, Vieth M, Jaspersen D, Labenz J, et al. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut 2005;54:746-51.
17. Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease: an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003;18:767-76.
18. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999;117:11-6.
19. Calleja JL, Suarez M, De Tejada AH, Navarro A, the Pantogerd Group. Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole. Dig Dis Sci 2005;50:432-9.
20. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Klokman JJ, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004;53:12-20.
21. Peters FTM, Kuipers EJ, Ganesh S, Sluiter WJ, Klinkenberg-Knol EC, Lamers CBHW, et al. The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy. Aliment Pharmacol Ther 1999;13:921-6.
22. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SGM. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999;94:884-7.
23. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 2000;118:661-9.
24. Vakil NB, Traxler BM, Levine D. Symptom response and healing of erosive esophagitis with proton-pump inhibitors in patients with Helicobacter pylori infection. Am J Gastroenterol 2004;99:1437-41.
25. De Wit NJ, De Boer WA, Geldof H, Hazelhoff B, Bergmans P, Tytgat GNJ, et al. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness? Aliment Pharmacol Ther 2004;20:451-8.
26. Van der Ende A, van der Hulst RWM, Roorda P, Tytgat GNJ, Dankert J. Evaluation of three commercial serological tests with different methodologies to assess Helicobacter pylori infection. J Clin Microbiol 1999;37:4150-2.
27. Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL. A randomized double-blind comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002;16:479-85.
28. Sloan S, Jokubaitis L, Camacho F, Perdomo C, Light M, Delchier JC. Rabeprazole provides better heartburn relief compared to omeprazole in the first 3 and 7 days of treatment. Gut 2000;47 Suppl III:A62.
29. Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 2002;16:445-54.
30. Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002;97:1332-9.
31. Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003;17:1507-14.
32. Bruley des Varannes S, Gharib H, Bicheler V, Bost R, Bonaz B, Stanescu, et al. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. Aliment Pharmacol Ther 2004;20:899-907.
33. Barth JA, Gardner JD, Sloan S. Rabeprazole vs omeprazole: onset, duration and magnitude of gastric antisecretory effects. Gut 2000;47 Suppl III:A61.
34. Ohning GV, Walsh JH, Pisegna JR, Murthy A, Barth J, Kovacs TOG. Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects. Aliment Pharmacol Ther 2003;17:1109-14.
35. Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N. Effects of rabeprazole 20 mg or esomeprazole 20 mg on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002;16:1301-7.
36. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24 hour intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998;12:1079-89.
37. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schutze K, et al. Expo Study Investigators. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005;21:739-46.
38. Armstrong D, Talley NJ, Lauritsen K, Moum B, Lind T, Tunturi-Hihnala H, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004;20:413-21.